248 related articles for article (PubMed ID: 17710613)
21. A spreadsheet program for modeling quantitative structure-pharmacokinetic relationships for inhaled volatile organics in humans.
Béliveau M; Krishnan K
SAR QSAR Environ Res; 2005; 16(1-2):63-77. PubMed ID: 15844443
[TBL] [Abstract][Full Text] [Related]
22. An integrated QSPR-PBPK modelling approach for in vitro-in vivo extrapolation of pharmacokinetics in rats.
Kamgang E; Peyret T; Krishnan K
SAR QSAR Environ Res; 2008; 19(7-8):669-80. PubMed ID: 19061083
[TBL] [Abstract][Full Text] [Related]
23. Revised assessment of cancer risk to dichloromethane: part I Bayesian PBPK and dose-response modeling in mice.
Marino DJ; Clewell HJ; Gentry PR; Covington TR; Hack CE; David RM; Morgott DA
Regul Toxicol Pharmacol; 2006 Jun; 45(1):44-54. PubMed ID: 16442684
[TBL] [Abstract][Full Text] [Related]
24. Pulmonary bioactivation of trichloroethylene to chloral hydrate: relative contributions of CYP2E1, CYP2F, and CYP2B1.
Forkert PG; Baldwin RM; Millen B; Lash LH; Putt DA; Shultz MA; Collins KS
Drug Metab Dispos; 2005 Oct; 33(10):1429-37. PubMed ID: 15987776
[TBL] [Abstract][Full Text] [Related]
25. Physiologically based pharmacokinetic (PBPK) modeling of caffeine and theophylline in neonates and adults: implications for assessing children's risks from environmental agents.
Ginsberg G; Hattis D; Russ A; Sonawane B
J Toxicol Environ Health A; 2004 Feb; 67(4):297-329. PubMed ID: 14713563
[TBL] [Abstract][Full Text] [Related]
26. Kinetic modeling of beta-chloroprene metabolism: II. The application of physiologically based modeling for cancer dose response analysis.
Himmelstein MW; Carpenter SC; Evans MV; Hinderliter PM; Kenyon EM
Toxicol Sci; 2004 May; 79(1):28-37. PubMed ID: 14976335
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of the impact of the exposure route on the human kinetic adjustment factor.
Valcke M; Krishnan K
Regul Toxicol Pharmacol; 2011 Mar; 59(2):258-69. PubMed ID: 20969910
[TBL] [Abstract][Full Text] [Related]
28. Physiologically based modeling of the inhalation pharmacokinetics of ethylbenzene in B6C3F1 mice.
Nong A; Charest-Tardif G; Tardif R; Lewis DF; Sweeney LM; Gargas ML; Krishnan K
J Toxicol Environ Health A; 2007 Nov; 70(21):1838-48. PubMed ID: 17934956
[TBL] [Abstract][Full Text] [Related]
29. Physiologically based pharmacokinetic modeling of inhaled trichloroethylene and its oxidative metabolites in B6C3F1 mice.
Greenberg MS; Burton GA; Fisher JW
Toxicol Appl Pharmacol; 1999 Feb; 154(3):264-78. PubMed ID: 9931286
[TBL] [Abstract][Full Text] [Related]
30. A human physiologically based pharmacokinetic model for trichloroethylene and its metabolites, trichloroacetic acid and free trichloroethanol.
Fisher JW; Mahle D; Abbas R
Toxicol Appl Pharmacol; 1998 Oct; 152(2):339-59. PubMed ID: 9853003
[TBL] [Abstract][Full Text] [Related]
31. Do endogenous volatile organic chemicals measured in breath reflect and maintain CYP2E1 levels in vivo?
Mathews JM; Raymer JH; Etheridge AS; Velez GR; Bucher JR
Toxicol Appl Pharmacol; 1997 Oct; 146(2):255-60. PubMed ID: 9344893
[TBL] [Abstract][Full Text] [Related]
32. Physiologically based pharmacokinetic models for the transport of trichloroethylene in adipose tissue.
Albanese RA; Banks HT; Evans MV; Potter LK
Bull Math Biol; 2002 Jan; 64(1):97-131. PubMed ID: 11868339
[TBL] [Abstract][Full Text] [Related]
33. Use of tissue disposition data from rats and dogs to determine species differences in input parameters for a physiological model for perchloroethylene.
Dallas CE; Chen XM; Muralidhara S; Varkonyi P; Tackett RL; Bruckner JV
Environ Res; 1994 Oct; 67(1):54-67. PubMed ID: 7925194
[TBL] [Abstract][Full Text] [Related]
34. Physiological-model-based derivation of the adult and child pharmacokinetic intraspecies uncertainty factors for volatile organic compounds.
Pelekis M; Gephart LA; Lerman SE
Regul Toxicol Pharmacol; 2001 Feb; 33(1):12-20. PubMed ID: 11259175
[TBL] [Abstract][Full Text] [Related]
35. Predicting cancer risk from vinyl chloride exposure with a physiologically based pharmacokinetic model.
Reitz RH; Gargas ML; Andersen ME; Provan WM; Green TL
Toxicol Appl Pharmacol; 1996 Apr; 137(2):253-67. PubMed ID: 8661351
[TBL] [Abstract][Full Text] [Related]
36. Physiologically-based pharmacokinetic and toxicokinetic models in cancer risk assessment.
Krishnan K; Johanson G
J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2005; 23(1):31-53. PubMed ID: 16291521
[TBL] [Abstract][Full Text] [Related]
37. Development of a physiologically based pharmacokinetic (PBPK) model for methyl iodide in rats, rabbits, and humans.
Sweeney LM; Kirman CR; Gannon SA; Thrall KD; Gargas ML; Kinzell JH
Inhal Toxicol; 2009 May; 21(6):552-82. PubMed ID: 19519155
[TBL] [Abstract][Full Text] [Related]
38. Application of PBPK modeling in support of the derivation of toxicity reference values for 1,1,1-trichloroethane.
Lu Y; Rieth S; Lohitnavy M; Dennison J; El-Masri H; Barton HA; Bruckner J; Yang RS
Regul Toxicol Pharmacol; 2008 Mar; 50(2):249-60. PubMed ID: 18226845
[TBL] [Abstract][Full Text] [Related]
39. A distributed parameter physiologically-based pharmacokinetic model for dermal and inhalation exposure to volatile organic compounds.
Roy A; Weisel CP; Lioy PJ; Georgopoulos PG
Risk Anal; 1996 Apr; 16(2):147-60. PubMed ID: 8638037
[TBL] [Abstract][Full Text] [Related]
40. A gas-liquid system for enzyme kinetic studies of volatile organic chemicals. Determination of enzyme kinetic constants and partition coefficients of trichloroethylene.
Hwang IY; Reardon KF; Tessari JD; Yang RS
Drug Metab Dispos; 1996 Apr; 24(4):377-82. PubMed ID: 8801050
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
